Branko Cuglievan, MD
Department of Pediatrics, Division of Pediatrics
About Dr. Branko Cuglievan
Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology training at MD Anderson, during which he was selected the Chief Fellow. He obtained board certification in Pediatrics and Pediatric Hematology and Oncology and stayed on faculty as Assistant Professor in the Department of Pediatrics.
Dr. Cuglievan focuses on Pediatric Leukemia and Lymphoma and collaborates extensively with the prestigious adult divisions of Leukemia and Lymphoma and is either the principal investigator or the pediatric collaborator for several pivotal trials that cover the Adolescents and Young Adult (AYA) population. Additionally, he leads the Pediatric Leukemia and Lymphoma service at Memorial Hermann Children's Hospital.
His translational research work is done in collaboration with the Massachusetts Institute of Technology and Harvard University and has been focused on the implementation of biomedical engineering devices to accelerate drug discovery for pediatric cancer. He has received several awards, including the Young Investigator Hyundai Hope on wheels, Tridelta Foundation award, and the Men of Distinction Foundation award. Dr. Cuglievan has authored/co-authored several publications and book chapters and serves as MD Anderson's Faculty Ambassador for MLS' Houston Dynamo.
Present Title & Affiliation
Primary Appointment
Section Chief, Leukemia/Lymphoma, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Biomedical Engineering to accelerate drug discovery in Childhood Cancer
Education & Training
Degree-Granting Education
2010 | Universidad de San Martin de Porres, Facultad de Medicina Humana, Lima, PER, MD, Medicine |
2009 | Harvard Medical School, Boston Children's Hospital, Boston, ME, USA, Pediatrics, Pediatrics |
2001 | Markham College, Lima, PER, Bilingual Diploma, International Baccalaureate |
Postgraduate Training
2015-2018 | Clinical Fellowship, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
2013-2015 | Clinical Residency, Pediatrics, Miami Children's Hospital, Miami, FL |
2012-2013 | Clinical Internship, Pediatrics, Miami Children's Hospital, Miami, FL |
Board Certifications
2019 | The American Board of Pediatric Hematology-Oncology |
2015 | The American Board of Pediatrics |
Experience & Service
Administrative Appointments/Responsibilities
Section Chief ad interim, Leukemia/Lymphoma, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2022
Other Appointments/Responsibilities
Member, Infectious Disease Committee, Miami Children's Hospital, Miami, FL, 2015 - 2015
Representative of Class 2015, Miami Children's Hospital, Miami, FL, 2012 - 2015
Physician, Clinica Anglo Americana, Lima, 2010 - 2012
Member, Academic Commission, Universidad San Martin de Porres, Lima, 2006 - 2006
Member, Student Council, Universidad San Martin de Porres, Lima, 2005 - 2005
Institutional Committee Activities
Chair, Pediatrics Hematology/Oncology Fellowship Program Evaluation Committee, 2019 - Present
Committee Representative for Pediatrics, Clinical Learning Environment Review (CLER), 2018 - Present
Member, Pediatric Division Travel Policy Committee, 2018 - Present
Member, Pediatrics Clinical Practice Committee, 2017 - Present
Member, Ewing's Sarcoma and Osteosarcoma Working Group, 2017 - Present
Member, Pediatric Leukemia/Lymphoma Working Group, 2017 - Present
Member, Pediatric Education Working Group, 2017 - Present
Honors & Awards
2018 | Chief Fellow, The University of Texas MD Anderson Cancer Center |
2018 | Young Investigator Award, Hyundai Hope on Wheels |
2018 | Nominee for the Resident/Fellow Excellence Award for Professionalism, The University of Texas MD Anderson Cancer Center |
2018 | Elected representative for the Clinical Learning Environment Review (CLER) committee for Pediatrics, The University of Texas MD Anderson Cancer Center |
2015 | 1st Place Award - 7th Annual Scholarship Day, Miami Children's Hospital |
2015 | The Ramon Rodriguez Award for Preventative Pediatric Medicine, Miami Children's Hospital |
2015 | The Augustin Castellanos Resident of the Year Award, Miami Children's Hospital |
2015 | "Speed Data-ing” Fellowship Award, The University of Texas MD Anderson Cancer Center |
2014 | 1st Place Award - 6th Annual Scholarship Day, Miami Children's Hospital |
2014 | Award for Excellence in Pediatric Hematology/Oncology, Miami Children's Hospital |
2013 | 1st Place Award - 5th Annual Scholarship Day, Miami Children's Hospital |
2012 | Resident of the Month, Miami Children's Hospital |
2003 | Ranked #1 Medical School Admission Exam - Int'l Baccalaureate Category, Universidad San Martin de Porres |
2002 | President, Markham College |
2001 | Perfect Leadership Award, Markham College |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Martin SD, Davis ES, Dai C, Boal LH, Araya B, Brackett J, Dickens D, Kahn A, Martinez I, Sharma A, Schwalm C, Aguayo-Hiraldo P, Bhatia S, Levine JM, Johnston EE, Wolfson JA, Pediatric Oncology COVID-19 Case Consortium. Clinical Features and Risk Factors Associated With Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19. JAMA Oncol 9(8):1108-1112, 2023. e-Pub 2023. PMID: 37166782.
- Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica. e-Pub 2023. PMID: 37646654.
- Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia. e-Pub 2023. PMID: 37452102.
- Munir F, Hardit V, Sheikh IN, AlQahtani S, He J, Cuglievan B, Hosing C, Tewari P, Khazal S. Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int J Mol Sci 24(12), 2023. e-Pub 2023. PMID: 37373245.
- Pagano L, Zinzani PL, Pileri S, Quaglino P, Cuglievan B, Berti E, Pemmaraju N, Onida F, Willemze R, Orfao A, Barosi G. Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel. Hemasphere 7(3):e841, 2023. e-Pub 2023. PMID: 36844178.
- Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. e-Pub 2023. PMID: 36892949.
- Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. e-Pub 2023. PMID: 36922593.
- Trabal A, Gibson A, He J, McCall D, Roth M, Nuñez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046645.
- Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov IN, Cuglievan B, Dave H, Deyell R, Flerlage JE, Franklin ARK, Krajewski J, Leger KJ, Marks LJ, Norris RE, Pacheco M, Willen FK, Yan AP, Harker-Murray P, Giulino-Roth L. Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood Adv. e-Pub 2023. PMID: 36897253.
- Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Sr S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
- Rav ES, Wahba A, Patnaik A, Toruner G, Hittle A, Toepfer L, Roth M, Cuglievan B, Nunez C, McCall D. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome. Pediatr Blood Cancer:e30191. e-Pub 2023. PMID: 36602024.
- Cuglievan B, McCall D, Robusto L, Mireles ME, Gettys SC. Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia. Expert Opin Pharmacother. e-Pub 2022. PMID: 36346029.
- Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood. e-Pub 2022. PMID: 36399715.
- Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen C, Angelucci E, Vinti L, Mughal TI, Pawlowska A. AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S244-S245, 2022. PMID: 36163828.
- McCall D, Jabbour E, Roth M, Nunez C, |Cuglievan B. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. Pediatr Blood Cancer:e29939. e-Pub 2022. PMID: 36031729.
- Garces S, Rudzki Z, Yin CC, Miranda RN, Medina AM, Sriganeshan V, Cuglievan B, Li S, Xu J, Jelloul F, Khoury JD, Thakral B, Tang G, Garces JC, Medeiros LJ. MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy: Potential Utility in Diagnosis and Differential Diagnosis. Am J Surg Pathol. e-Pub 2022. PMID: 35877199.
- Berkman AM, Andersen CR, Cuglievan B, McCall DC, Lupo PJ, Parsons SK, DiNardo CD, Short NJ, Jain N, Kadia TM, Livingston JA, Roth ME. Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiol Biomarkers Prev 31(6):1176-1184, 2022. PMID: 35553621.
- Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, Wu CC, Beird HC, Porter RW, Ingram DR, Ramamoorthy V, Mohiuddin S, McCall D, Truong DD, Cuglievan B, Futreal PA, Velasco AR, Anvar NE, Utama B, Titus M, Lazar AJ, Wang WL, Rodriguez-Aguayo C, Ratan R, Livingston JA, Rai K, MacLeod AR, Daw NC, Hayes-Jordan A, Ludwig JA. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun 13(1):3057, 2022. e-Pub 2022. PMID: 35650195.
- Sheikh I, Nunez C, McCall D, Roth M, Cuglievan B. Programmed Cell Death Protein Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation in an Adolescent Patient. Pediatr Blood Cancer 69(3):e29390, 2022. e-Pub 2021. PMID: 35077016.
- Roth M, Berkman A, Andersen CR, Cuglievan B, Andrew Livingston J, Hildebrandt M, Bleyer A. Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. Oncologist 27(2):135-143, 2022. PMID: 35641206.
- Garces S, Medeiros LJ, Marques-Piubelli ML, Coelho Siqueira SA, Miranda RN, Cuglievan B, Sriganeshan V, Medina AM, Garces JC, Saluja K, Bhattacharjee MB, Khoury JD, Li S, Xu J, Jelloul FZ, Thakral B, Cameron Yin C. Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation. Hum Pathol. e-Pub 2022. PMID: 34995673.
- Qiu L, Nunez CA, Tang G, Cuglievan B, Issa GC, Wang SA, Medeiros LJ, Thakral B. A rare case of acute megakaryoblastic leukemia with t(11;17)(q23;q21) and KMT2A::MLLT6 fusion. Ann Hematol. e-Pub 2022. PMID: 35091795.
- Molina ER, Chim LK, Lamhamedi-Cherradi SE, Mohiuddin S, McCall D, Cuglievan B, Krishnan S, Porter RW, Ingram DR, Wang WL, Lazar AJ, Scott DW, Truong DD, Daw NC, Ludwig JA, Mikos AG. Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget 13:521-533, 2022. e-Pub 2022. PMID: 35284040.
- Vallejo FA, Sanchez A, Cuglievan B, Walters WM, De Angulo G, Vanni S, Graham RM. NAMPT Inhibition Induces Neuroblastoma Cell Death and Blocks Tumor Growth. Front Oncol 12:883318, 2022. e-Pub 2022. PMID: 35814452.
- Ragoonanan D, Bhar S, Mohan G, Beltramo F, Khazal SJ, Hurley C, Andersen C, Margossian S, Neelapu SS, Shpall E, Gutierrez C, Tewari P, Shoberu B, Talleur A, McCall D, Nunez C, Cuglievan B, Tambaro FP, Petropoulos D, Abdel-Azim H, Mahadeo KM. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Front Oncol 12:1022901, 2022. e-Pub 2022. PMID: 36353531.
- Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, Ludwig JA. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther 28(12):1325-1338, 2021. e-Pub 2021. PMID: 33408328.
- Berkman AM, Andersen CR, Puthenpura V, Livingston JA, Ahmed S, Cuglievan B, Hildebrandt MAT, Roth ME. Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. Cancer Epidemiol 75:102044, 2021. e-Pub 2021. PMID: 34597882.
- Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008312.
- Wahba A, Cuglievan B. Central nervous system Langerhans cell histiocytosis and neurodegenerative syndrome responding to MEK inhibition. EJHaem 2(4):881-882, 2021. e-Pub 2021. PMID: 35845219.
- Baig MU, Rytting M, Roth M, Morani AC, Nunez C, Lin P, Cuglievan B. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma. J Pediatr Hematol Oncol 43(7):e991-e996, 2021. e-Pub 2021. PMID: 33480649.
- Berkman AM, Andersen CR, Puthenpura V, Livingston JA, Ahmed S, Cuglievan B, Hildebrandt MAT, Roth ME. Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. Cancer Epidemiol Biomarkers Prev 30(9):1717-1725, 2021. e-Pub 2021. PMID: 34244160.
- Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan B. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives. Paediatr Drugs 23(5):457-463, 2021. e-Pub 2021. PMID: 34351604.
- Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
- McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver NG, Kadia TM, DiNardo CD, Yi JS, Cuglievan B. Gilteritinib Combination Therapies in Pediatric Patients with FLT3 Mutated Acute Myeloid Leukemia. Blood Adv. e-Pub 2021. PMID: 34592761.
- Flerlage JE, Hiniker SM, Armenian S, Benya EC, Bobbey AJ, Chang V, Cooper S, Coulter DW, Cuglievan B, Hoppe BS, Isenalumhe L, Kelly K, Kersun L, Lamble AJ, Larrier NA, Magee J, Oduro K, Pacheco M, Price AP, Roberts KB, Smith CM, Sohani AR, Trovillion EM, Walling E, Xavier AC, Burns JL, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. J Natl Compr Canc Netw 19(6):733-754, 2021. e-Pub 2021. PMID: 34214968.
- Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. e-Pub 2021. PMID: 33951890.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. e-Pub 2021. PMID: 33731864.
- Kadipasaoglu C, Wahba A, Bhattacharjee MB, Cuglievan B, Fletcher SA. Hemorrhagic Giant Cell Tumor of the Occipital Skull Base: A Case Report and Literature Review. Cureus 13(3):e13832, 2021. e-Pub 2021. PMID: 33859893.
- Strati P, Cheng PTM, Steiner RE, Alcedo Andrade PE, Feng L, Sano D, Rao VA, Singh P, Miranda R, Gunther JR, Pinnix CC, Dabaja BS, Cuglievan B, Xing K, Villa D, Skinnider B, Sehn LH, Connors JM, Nieto Y, Ahmed S, Lee HJ, Savage KJ. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol 192(3):560-567, 2021. PMID: 33517581.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. e-Pub 2021. PMID: 33608690.
- Hernandez Tejada FN, Zamudio A, Marques-Piubelli ML, Cuglievan B, Harrison D. Advances in the Management of Pediatric Sarcomas. Curr Oncol Rep 23(1):3, 2020. e-Pub 2020. PMID: 33196879.
- McCall D, Tewari P, Kass JDA, Cuglievan B. The Evolution of the Pediatric Hematology/Oncology Fellowship: What Does it Mean to be Productive?. J Pediatr Hematol Oncol 42(6):e544-e545, 2020. PMID: 32032246.
- Davies K, Barth M, Armenian S, Audino AN, Barnette P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, Marks L, Page K, Reilly AF, Weinstein JL, Xavier AC, McMillian NR, Freedman-Cass DA. Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(8):1105-1123, 2020. PMID: 32755986.
- Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32630797.
- Cuglievan B, Berkman A, Dibaj S, Wang J, Andersen CR, Livingston JA, Gill J, Bleyer A, Roth M. Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. J Adolesc Young Adult Oncol. e-Pub 2020. PMID: 32678703.
- Cabrera TB, Wang W, Yedururi S, Slopis JM, Steiner RE, Rytting ME, Cuglievan B. Coincidental Expression of Classic Hodgkin Lymphoma and Neurofibromatosis Type I and Literature Review. J Pediatr Hematol Oncol. e-Pub 2020. PMID: 32366782.
- Molina ER, Chim LK, Salazar MC, Koons GL, Menegaz BA, Ruiz-Velasco A, Lamhamedi-Cherradi SE, Vetter AM, Satish T, Cuglievan B, Smoak MM, Scott DW, Ludwig JA, Mikos AG. 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization. ACS Biomater Sci Eng 6(1):539-552, 2020. e-Pub 2019. PMID: 33463239.
- Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson P, et al. Desmoplastic Small Round Cell Tumor: A Multidisciplinary Approach That Improves Patient Survival. Clinical Cancer Research, 2020.
- Cuglievan B, Subbiah V, Meric-Bernstam F, Herzog C. Response to mTOR-based therapy and incidental finding of Lynch syndrome in a patient with solid pseudopapillary neoplasm of the pancreas with AKT1_E17K mutation. JCO Precision Oncology, 2020.
- Molina ER, Chim LK, Salazar MC, Mehta SM, Menegaz BA, Lamhamedi-Cherradi SE, Satish T, Mohiuddin S, McCall D, Zaske AM, Cuglievan B, Lazar AJ, Scott DW, Grande-Allen JK, Ludwig JA, Mikos AG. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomater 100:38-51, 2019. e-Pub 2019. PMID: 31542501.
- Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Domínguez S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frías MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Simón L, Fabre M, Carcaboso ÁM, Ludwig JA, de Álava E. Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma. Clin Cancer Res 25(7):2228-2240, 2019. e-Pub 2018. PMID: 30420447.
- Molina Eric R., Chim LK, Salazar MC, Koons, Menegaz BA, Alejandra Ruiz-Velasco, Salah-Eddine Lamhamedi-Cherradi, Amelia M. Vetter, Tejus Satish, Cuglievan B, Mollie M. Smoak, Scott DA, Ludwig JA. 3D Tissue-Engineered Tumor Model for Ewing’s Sarcoma That Incorporates Bone-like ECM and Mineralization. ACS Biomater. Sci. Eng, 2019.
- Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JA. Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res 24(19):4865-4873, 2018. e-Pub 2018. PMID: 29871905.
- Menegaz BA, Cuglievan B, Benson J, Camacho P, Lamhamedi-Cherradi SE, Leung CH, Warneke CL, Huh W, Subbiah V, Benjamin RS, Patel S, Daw N, Hayes-Jordan A, Ludwig JA. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist 23(3):360-366, 2018. e-Pub 2017. PMID: 29212731.
- Zapata CP, Cuglievan B, Zapata CM, Olavarrieta R, Raskin S, Desai K, De Angulo G. PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies. Pediatr Blood Cancer 65(2), 2018. e-Pub 2017. PMID: 28901637.
- Cuglievan B, Subbiah V, Wang H, Morani A, Meric-Bernstam F, Holla V, Herzog CE. Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31650099.
- Maher OM, Silva JG, Huh WW, Cuglievan B, DePombo A, Kebriaei P, Park M, Liu D, Tillman C, Tarek N, Cooper LJN, Tewari P. Etiologies and Impact of Readmission Rates in the First 180 Days After Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Young Adults. J Pediatr Hematol Oncol 39(8):609-613, 2017. PMID: 28859043.
- Cuglievan B, Menegaz BA, DePombo A, Morani AC, Miranda RN, Rytting M. A pediatric patient with glycogen storage disease type IA and Castleman disease. Pediatr Blood Cancer 64(8), 2017. e-Pub 2016. PMID: 28035790.
- Cuglievan B, Menegaz BA, Garces S, Rytting ME. Acute myeloid leukaemia masquerading as a primary CNS tumour. BMJ Case Rep 2017, 2017. e-Pub 2017. PMID: 28801332.
- Lahiri S, Cuglievan B, Gutierrez JL, Pefkarou A. Successful conservative treatment of myocardial infarction in a teenager with MTHFR mutation. Int J Cardiol Heart Vasc 15:24-25, 2017. e-Pub 2017. PMID: 28616569.
- Cuglievan B, Miranda RN. Kikuchi-Fujimoto disease. Blood 129(7):917, 2017. PMID: 28209753.
Abstracts
- Kok Hoe Chan, Jeremy Ramdial, Chitra Hosing, Samer Srour, Amin Alousi, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Sairah Ahmed, Swaminathan Iyer, Hun Lee, Ranjit Nair, Raphael Steiner, Paolo Strati, Bouthaina Dabaja, Penny Fang, Jillian Gunther, Chelsea Pinnix, Susan Wu, Branko Cuglievan, Kris Mahadeo, Richard Champlin, Elizabeth J Shpall, Yago Nieto. Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing After an Autologous Stem-Cell Transplant (ASCT), 2022.
- Oren Pasvolsky1,2,3, Roland L. Bassett4, Sassine Ghanem 5, Branko Cuglievan, Priti Tewari6, Chitra Hosing1, Samer Srour1, Jeremy Ramdial1, Uday Popat1, Muzaffar Qazilbash1, Partow Kebriaei1, Richard Champlin1, Elizabeth J. Shpall1, Yago Nieto1. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant, 2022.
- Cuglievan, B, McCall, D.. The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy For DSRCT, 2022.
- Qing Deng, PhD , Cem Meydan, PhD , Priya Lakra, PhD , Darko Barisic ,Christopher R Chin , Estela Rojas-Neira , Vida Ravenmehr , Jared Henderson,PhD , Panhong Gou , Nader Kim El-Mallawany, MD , Carl Allen, MD, PhD , Branko Cuglievan, MD , Francisco Vega, MD, PhD , Christopher E Mason, PhD , AriMelnick, MD and Michael R Green, PhD. Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma, 2022.
- Ghayas Issa, Branko Cuglievan, Eytan Stein, Martha Arellano, Andrius Zucenka, Nandita Khera, Richard Stone, Michael Thirman, John Dipersio, Yu Gu, Rebecca Bagley, David Tamang, Kim Dishman, Michael Meyers, Kate Madigan, Nicole McNeer, Ibrahim Aldoss. Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience, 2022.
- Ghayas C. Issa, MD, Ibrahim Aldoss, MD, John DiPersio, MD PhD, Branko Cuglievan, MD, Richard Stone, MD, Martha Arellano, MD, Michael Thirman, MD, Manish Patel, MD, David Dickens, MD, Neerav Shukla, MD, Rebecca G. Bagley, MA, Michael L. Meyers, MD PhD, Kate Madigan, MD, Peter Ordentlich, PhD, Yu Gu, PhD, Steven Smith, PhD, Gerard McGeehan, PD, and Eytan Stein, MD. The Menin Inhibitor SNDX-5613 (revumenib) leads to Durable Responses in Patients with KMT2A-rearranged or NPM1 mutant AML: Results of a Phase 1 study, 2022.
- Naveen Pemmaraju, Branko Cuglievan, Joseph Lasky, Albert Kheradpour, Nobuko Hijiya, Anthony S. Stein, Soheil Meshinchi, Craig Mullen, Emanuele Angelucci, Luciana Vinti, Tariq I. Mughal, Anna Pawlowska. Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy. "EHA", 2022.
- Daniel Nguyen, Jing Ning, Wei Qiao, Koji Sasaki, Hagop M. Kantarjian, Nicholas James Short, Branko Cuglievan, Naval Guastad Daver, Courtney Denton Dinardo, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Ghayas C. Issa. Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality, 2022.
- Amber Gibson, Adriana Trabal, David McCall, Laurie Toepfer, Michael Roth, Kris Mahadeo, Branko Cuglievan. Venetoclax For Acute Lymphoblastic Leukemia In Pediatric Patients, 2021.
- Amber Gibson, Adriana Trabal, David Mccall, Laurie Toepfer, Michael Roth, Kris Mahadeo, Branko Cuglievan. Venetoclax For Acute Myeloid Leukemia In Pediatric Patients: The Md Anderson Cancer Center Experience, 2021.
- Adriana Trabal, Amber Gibson, David McCall, Michael Roth, Cesar Nuñez, Kris Mahadeo, Sajad Khazal, Meredith Buzbee, Laurie Toepfer, Naval Daver, Tapan Kadia, Nicholas Short, Ghayas Issa, Farhad Ravandi, Courtney Dinardo, Sofia Garces, Andrea Marcogliese, Hana Paek, Zoann Dreyer, Julienne Brackett, Michele Redell, Joanna Yi, Guillermo Garcia-Manero, Hagop Kantarjian, Marina Konopleva, Alexandra Stevens, and Branko Cuglievan. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration, 2021.
- Cuglievan, B, Rytting, M. Castleman’s disease in a patient with Glycogen Storage Disease type 1a, 2016.
- Ahlstrom,K , Cuglievan, B., Craven, P, Gatliff, M, Shephard, M, Tewari, P. Implementation of parameter transfusion orders for stem cell transplant recipients results in increased nursing autonomy, decreased transfusion delays, and improved patient care”, 2016.
- Zapata, C, Olavarrieta, R Raskin S, Zapata CA, Cuglievan, B, Desai, K, De Angulo, G. The role of PET/CT vs. Bone marrow biopsy in the initial evaluation of bone marrow infiltration in pediatric Non Hodgkin lymphoma, 2015.
- Zapata, C, Olavarrieta, R Raskin S, Zapata CA, Cuglievan, B, Desai, K, De Angulo, G.. The role of PET/CT vs. Bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric solid tumors, 2015.
- Zapata, C, Olavarrieta, R Raskin S, Zapata CA, Cuglievan, B., Desai, K, De Angulo, G. The role of PET/CT vs. Bone marrow biopsy in the initial evaluation of bone marrow infiltration in pediatric Non Hodgkin lymphoma. Fifth international Symposium on childhood, adolescent and young adult Non Hodgkin Lymphoma, 2015.
- Zhang B, Cuglievan B, Vanni S, Komotar RJ, Graham RM. Targeting glioblastoma stem cells with withaferin A, 2014.
- Cuglievan B, Hernandez F, De Angulo G, Vanni S, Graham R. The role of NAMPT-NAD-Sirtuin pathway in neuroblastoma chemoresistance, 2014.
- Morrison A., Cuglievan B, Khatib, Z.. Intracranial calcifications in pediatric brain tumor patients after receiving proton beam therapy, 2013.
- Cuglievan B, Galvez,J., De Angulo, G.. Epstein Barr Infection obscuring Pediatric chronic eosinophilic leukemia associated t(1;5) with excellent response to targeted therapy, 2013.
- Morrison A., Cuglievan B, Khatib, Z.. Intracranial calcifications calcifications in pediatric brain tumor patients after receiving proton beam therapy, 2013.
Letters to the Editor
- Cuglievan B, DePombo A, De Angulo G. Aplastic anemia: the correct nomenclature matters. Haematologica/haematol 101, 2016.
Patient Reviews
CV information above last modified September 19, 2024